CARMIL1 regulates liver cancer cell proliferation by activating the ERK/mTOR pathway through the TRIM27/p53 axis
International Immunopharmacology · 2024-06 · 134 · 112139
DOI: 10.1016/j.intimp.2024.112139 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-06. Verfasst von Yuzhen Ge und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Prdiatric Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, PR China. Hauptthemen laut MEDLINE: Cell Proliferation, Liver Neoplasms, TOR Serine-Threonine Kinases, Tripartite Motif Proteins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Capping protein regulatory factor and myosin 1 linker 1 is termed CARMIL1. CARMIL1 is involved in several physiological processes; it forms an actin filament network and plasma membrane-bound cellular projection tissues and positively regulates the cellular components and tissues. CARMIL1 exhibits important biological functions in cancer; nonetheless, these functions have not been completely explored. We aimed to investigate the novel functions of CARMIL1 in liver cancer, particularly in cell proliferation. The cell counting kit-8, 5-ethynyl-2'-deoxyuridine, Component A experiments, and subcutaneous tumor formation model suggest that CARMIL1 is central to the proliferation of liver cancer cells both in vivo and in vitro. We extracted CARMIL1 samples from The Cancer Genome Atlas Program and analyzed its enrichment. CARMIL1 regulated the pathway activity by affecting the expression of star molecular proteins of the extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin (mTOR). Moreover, it influenced the proliferation ability of liver cancer cells. Western blotting suggested that CARMIL1 downregulation could affect ERK and mTOR phosphorylation. Results of the co-immunoprecipitation demonstrated that CARMIL1 binds to tripartite motif (TRIM)27, which in turn binds to p53. Subsequently, CARMIL1 can regulate p53 stability and promote its degradation through TRIM27. Additionally, CARMIL1 inhibition enhanced the sensitivity of liver cancer cells to sorafenib. Tumor growth was significantly inhibited in the group treated with sorafenib and CARMIL1, compared with the group treated with CARMIL1 alone. Sorafenib is a first-line targeted chemotherapeutic drug for hepatocellular carcinoma treatment. It increases the long-term survival of hepatocellular carcinoma by 44%. In this study, downregulated CARMIL1 combined with sorafenib significantly reduced the tumor volume and weight of the mouse subcutaneous tumor model, indicating the potential possibility of combining CARMIL1 with sorafenib in hepatocellular carcinoma treatment. In summary, CARMIL1 promotes liver cancer cell proliferation by regulating the TRIM27/p53 axis and activating the ERK/mTOR pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Prdiatric Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, PR China.
- Department of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, PR China.
- Department of Liver Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, PR China.
- Department of Prdiatric Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, PR China. Electronic address: huajiangu9@163.com.
- Department of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, PR China; Department of Liver Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, PR China; Precision Medicine Research Ins…
Zitieren
APA
Ge, Y., Xiao, B., Zhao, R., Li, B., Yang, S., He, K. F., Gu, H. J., & Zuo, S. (2024). CARMIL1 regulates liver cancer cell proliferation by activating the ERK/mTOR pathway through the TRIM27/p53 axis. International Immunopharmacology, 134, 112139. https://doi.org/10.1016/j.intimp.2024.112139
Vancouver
Ge Y, Xiao B, Zhao R, Li B, Yang S, He KF, et al. CARMIL1 regulates liver cancer cell proliferation by activating the ERK/mTOR pathway through the TRIM27/p53 axis. International Immunopharmacology. 2024;134:112139. doi:10.1016/j.intimp.2024.112139
BibTeX
@article{Ge2024,
author = {Ge, Yuzhen and Xiao, Benli and Zhao, Rui and Li, Bo and Yang, Sibo and He, Kun Feng and Gu, Hua Jian and Zuo, Shi},
title = {CARMIL1 regulates liver cancer cell proliferation by activating the ERK/mTOR pathway through the TRIM27/p53 axis},
journal = {International Immunopharmacology},
year = {2024},
volume = {134},
pages = {112139},
doi = {10.1016/j.intimp.2024.112139}
}
EUVIMED